{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:11:34Z","timestamp":1794924694447,"version":"4.9.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK137942"],"award-info":[{"award-number":["DK137942"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK098655"],"award-info":[{"award-number":["DK098655"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK133388"],"award-info":[{"award-number":["DK133388"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK108859"],"award-info":[{"award-number":["DK108859"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK124328"],"award-info":[{"award-number":["DK124328"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG067913"],"award-info":[{"award-number":["AG067913"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66296-5","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T03:33:38Z","timestamp":1763955218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-7006","authenticated-orcid":false,"given":"Rongya","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Tok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Andres-Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-8483","authenticated-orcid":false,"given":"Lars","family":"Gr\u00f8ntved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Burant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-6806","authenticated-orcid":false,"given":"Sheng","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-1831","authenticated-orcid":false,"given":"Miguel A.","family":"Lanaspa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-9595","authenticated-orcid":false,"given":"Norbert","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D.","family":"Copps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-508X","authenticated-orcid":false,"given":"Morris F.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"66296_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"66296_CR2","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jpeds.2012.11.017","volume":"162","author":"DE Brumbaugh","year":"2013","unstructured":"Brumbaugh, D. E. et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J. Pediatr. 162, 930\u2013936 e931 (2013).","journal-title":"J. Pediatr."},{"key":"66296_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547\u2013555 (2015).","journal-title":"Gastroenterology"},{"key":"66296_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40519-016-0315-3","volume":"21","author":"A Mosca","year":"2016","unstructured":"Mosca, A. et al. Beverage consumption and paediatric NAFLD. Eat. weight Disord.: EWD 21, 581\u2013588 (2016).","journal-title":"Eat. weight Disord.: EWD"},{"key":"66296_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"66296_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka, A. C. et al. Nonalcoholic steatohepatitis: a review. Jama 323, 1175\u20131183 (2020).","journal-title":"Jama"},{"key":"66296_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"66296_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133\u20132223 (2018).","journal-title":"Physiol. Rev."},{"key":"66296_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.aav3722","volume":"365","author":"B Chaurasia","year":"2019","unstructured":"Chaurasia, B. et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 365, 386\u2013392 (2019).","journal-title":"Science"},{"key":"66296_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu, V., Vacca, M., Virtue, S., Allison, M. & Vidal-Puig, A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology 158, 1899\u20131912 (2020).","journal-title":"Gastroenterology"},{"key":"66296_CR11","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.jhepr.2021.100305","volume":"3","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. & Henry, L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 3, 100305 (2021).","journal-title":"JHEP Rep."},{"key":"66296_CR12","doi-asserted-by":"crossref","unstructured":"Hosokawa, Y. et al. Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model. Hepatol Commun. 7, e0161 (2023).","DOI":"10.1097\/HC9.0000000000000161"},{"key":"66296_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng.3714","volume":"49","author":"LA Lotta","year":"2017","unstructured":"Lotta, L. A. et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat. Genet. 49, 17\u201326 (2017).","journal-title":"Nat. Genet"},{"key":"66296_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J. Hepatol. 68, 268\u2013279 (2018).","journal-title":"J. Hepatol."},{"key":"66296_CR15","doi-asserted-by":"crossref","unstructured":"Eslam, M. & George, J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat. Rev. Gastroenterol Hepatol 7, e0161(2019).","DOI":"10.1038\/s41575-019-0212-0"},{"key":"66296_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","volume":"31","author":"S Romeo","year":"2020","unstructured":"Romeo, S., Sanyal, A. & Valenti, L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 31, 35\u201345 (2020).","journal-title":"Cell Metab."},{"key":"66296_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"66296_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nm.4350","volume":"23","author":"MP Czech","year":"2017","unstructured":"Czech, M. P. Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23, 804\u2013814 (2017).","journal-title":"Nat. Med."},{"key":"66296_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen, T. et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J. Hepatol. 68, 1063\u20131075 (2018).","journal-title":"J. Hepatol."},{"key":"66296_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801 (2019).","journal-title":"J. Hepatol."},{"key":"66296_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/10408363.2019.1711360","volume":"57","author":"S Softic","year":"2020","unstructured":"Softic, S. et al. Fructose and hepatic insulin resistance. Crit. Rev. Clin. Lab Sci. 57, 308\u2013322 (2020).","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"66296_CR22","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","volume":"4","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. A researcher\u2019s guide to preclinical mouse NASH models. Nat. Metab. 4, 1632\u20131649 (2022).","journal-title":"Nat. Metab."},{"key":"66296_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","volume":"71","author":"M Trauner","year":"2022","unstructured":"Trauner, M. & Fuchs, C. D. Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 71, 194\u2013209 (2022).","journal-title":"Gut"},{"key":"66296_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan, N. & Cusi, K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diab. Endocrinol. 10, 284\u2013296 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"66296_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo, T. et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 36, 947\u2013968 (2024).","journal-title":"Cell Metab."},{"key":"66296_CR26","doi-asserted-by":"crossref","unstructured":"White, M. F. & Kahn, C. R. Insulin action at a molecular level - 100 years of progress. Mol. Metab. 20, 101304 (2021).","DOI":"10.1016\/j.molmet.2021.101304"},{"key":"66296_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","volume":"7","author":"MS Brown","year":"2008","unstructured":"Brown, M. S. & Goldstein, J. L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7, 95\u201396 (2008).","journal-title":"Cell Metab."},{"key":"66296_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cmet.2007.11.013","volume":"7","author":"SB Biddinger","year":"2008","unstructured":"Biddinger, S. B. et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 7, 125\u2013134 (2008).","journal-title":"Cell Metab."},{"key":"66296_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2008.06.006","volume":"8","author":"XC Dong","year":"2008","unstructured":"Dong, X. C. et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8, 65\u201376 (2008).","journal-title":"Cell Metab."},{"key":"66296_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s42255-023-00843-6","volume":"5","author":"JR Cook","year":"2023","unstructured":"Cook, J. R., Hawkins, M. A. & Pajvani, U. B. Liver insulinization as a driver of triglyceride dysmetabolism. Nat. Metab. 5, 1101\u20131110 (2023).","journal-title":"Nat. Metab."},{"key":"66296_CR31","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1073\/pnas.0914798107","volume":"107","author":"S Li","year":"2010","unstructured":"Li, S., Brown, M. S. & Goldstein, J. L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. USA 107, 3441\u20133446 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66296_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2006.04.005","volume":"3","author":"CM Taniguchi","year":"2006","unstructured":"Taniguchi, C. M. et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda\/zeta. Cell Metab. 3, 343\u2013353 (2006).","journal-title":"Cell Metab."},{"key":"66296_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12977","volume":"7","author":"N Kubota","year":"2016","unstructured":"Kubota, N. et al. Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat. Commun. 7, 12977 (2016).","journal-title":"Nat. Commun."},{"key":"66296_CR34","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41366-018-0062-9","volume":"42","author":"M Honma","year":"2018","unstructured":"Honma, M. et al. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers. Int J. Obes. (Lond.) 42, 1544\u20131555 (2018).","journal-title":"Int J. Obes. (Lond.)"},{"key":"66296_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1097-2765(05)00010-9","volume":"6","author":"I Shimomura","year":"2000","unstructured":"Shimomura, I. et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob\/ob mice. Mol. Cell 6, 77\u201386 (2000).","journal-title":"Mol. Cell"},{"key":"66296_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2337\/dc20-1644","volume":"44","author":"KW Ter Horst","year":"2021","unstructured":"Ter Horst, K. W. et al. Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease. Diab. care 44, 489\u2013498 (2021).","journal-title":"Diab. care"},{"key":"66296_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","volume":"91","author":"FW Sanders","year":"2016","unstructured":"Sanders, F. W. & Griffin, J. L. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol. Rev. Camb. Philos. Soc. 91, 452\u2013468 (2016).","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"66296_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/CIRCRESAHA.119.315246","volume":"126","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. Functional screening of candidate causal genes for insulin resistance in human preadipocytes and adipocytes. Circ. Res 126, 330\u2013346 (2020).","journal-title":"Circ. Res"},{"key":"66296_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younossi","year":"2012","unstructured":"Younossi, Z. M. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 91, 319\u2013327 (2012).","journal-title":"Medicine"},{"key":"66296_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","volume":"62","author":"ZM Younossi","year":"2013","unstructured":"Younossi, Z. M., Otgonsuren, M., Venkatesan, C. & Mishra, A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 62, 352\u2013360 (2013).","journal-title":"Metabolism"},{"key":"66296_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","volume":"26","author":"N Stefan","year":"2017","unstructured":"Stefan, N., Schick, F. & Haring, H. U. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 26, 292\u2013300 (2017).","journal-title":"Cell Metab."},{"key":"66296_CR42","first-page":"216","volume":"5","author":"R Kumar","year":"2017","unstructured":"Kumar, R. & Mohan, S. Non-alcoholic fatty liver disease in lean subjects: characteristics and implications. J. Clin. Transl. Hepatol. 5, 216\u2013223 (2017).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"66296_CR43","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12072-018-9916-4","volume":"13","author":"MA Niriella","year":"2019","unstructured":"Niriella, M. A. et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol. Int. 13, 314\u2013322 (2019).","journal-title":"Hepatol. Int"},{"key":"66296_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1677517","volume":"39","author":"R Younes","year":"2019","unstructured":"Younes, R. & Bugianesi, E. NASH in lean individuals. Semin Liver Dis. 39, 86\u201395 (2019).","journal-title":"Semin Liver Dis."},{"key":"66296_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/joim.13069","volume":"288","author":"B Zou","year":"2020","unstructured":"Zou, B. et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J. Intern. Med. 288, 139\u2013151 (2020).","journal-title":"J. Intern. Med."},{"key":"66296_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","volume":"22","author":"S Maier","year":"2021","unstructured":"Maier, S. et al. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev. Endocr. Metab. Disord. 22, 351\u2013366 (2021).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"66296_CR47","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2337\/db16-1167","volume":"66","author":"A Gastaldelli","year":"2017","unstructured":"Gastaldelli, A., Gaggini, M. & DeFronzo, R. A. Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the san antonio metabolism study. Diabetes 66, 815\u2013822 (2017).","journal-title":"Diabetes"},{"key":"66296_CR48","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 115, 1343\u20131351 (2005).","journal-title":"J. Clin. Investig."},{"key":"66296_CR49","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1073\/pnas.1423952112","volume":"112","author":"DF Vatner","year":"2015","unstructured":"Vatner, D. F. et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc. Natl. Acad. Sci. USA 112, 1143\u20131148 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66296_CR50","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","volume":"78","author":"E Lee","year":"2023","unstructured":"Lee, E., Korf, H. & Vidal-Puig, A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J. Hepatol. 78, 1048\u20131062 (2023).","journal-title":"J. Hepatol."},{"key":"66296_CR51","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan, N., Schick, F., Birkenfeld, A. L., Haring, H. U. & White, M. F. The role of hepatokines in NAFLD. Cell Metab. 35, 236\u2013252 (2023).","journal-title":"Cell Metab."},{"key":"66296_CR52","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41591-018-0048-0","volume":"24","author":"R Tao","year":"2018","unstructured":"Tao, R. et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat. Med. 24, 1058\u20131069 (2018).","journal-title":"Nat. Med."},{"key":"66296_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101703","volume":"71","author":"R Tao","year":"2023","unstructured":"Tao, R. et al. Hepatic follistatin increases basal metabolic rate and attenuates diet-induced obesity during hepatic insulin resistance. Mol. Metab. 71, 101703 (2023).","journal-title":"Mol. Metab."},{"key":"66296_CR54","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.tem.2010.02.008","volume":"21","author":"ML Brown","year":"2010","unstructured":"Brown, M. L. & Schneyer, A. L. Emerging roles for the TGFbeta family in pancreatic beta-cell homeostasis. Trends Endocrinol. Metab. 21, 441\u2013448 (2010).","journal-title":"Trends Endocrinol. Metab."},{"key":"66296_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2016.06.002","volume":"433","author":"JS Hansen","year":"2016","unstructured":"Hansen, J. S. & Plomgaard, P. Circulating follistatin in relation to energy metabolism. Mol. Cell Endocrinol. 433, 87\u201393 (2016).","journal-title":"Mol. Cell Endocrinol."},{"key":"66296_CR56","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1210\/jc.2004-0162","volume":"89","author":"AL Schneyer","year":"2004","unstructured":"Schneyer, A. L., Wang, Q., Sidis, Y. & Sluss, P. M. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J. Clin. Endocrinol. Metab. 89, 5067\u20135075 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"66296_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.devcel.2005.09.008","volume":"9","author":"TB Thompson","year":"2005","unstructured":"Thompson, T. B., Lerch, T. F., Cook, R. W., Woodruff, T. K. & Jardetzky, T. S. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell 9, 535\u2013543 (2005).","journal-title":"Dev. Cell"},{"key":"66296_CR58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/dbio.2001.0555","volume":"243","author":"H Amthor","year":"2002","unstructured":"Amthor, H. et al. Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev. Biol. 243, 115\u2013127 (2002).","journal-title":"Dev. Biol."},{"key":"66296_CR59","doi-asserted-by":"crossref","unstructured":"Derynck, R. & Budi, E. H. Specificity, versatility, and control of TGF-beta family signaling. Sci. Signal. 12, eaav5183 (2019).","DOI":"10.1126\/scisignal.aav5183"},{"key":"66296_CR60","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1210\/en.2010-0868","volume":"152","author":"J Hansen","year":"2011","unstructured":"Hansen, J. et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology 152, 164\u2013171 (2011).","journal-title":"Endocrinology"},{"key":"66296_CR61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2015-3668","volume":"101","author":"JS Hansen","year":"2016","unstructured":"Hansen, J. S. et al. Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio. J. Clin. Endocrinol. Metab. 101, 550\u2013560 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"66296_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/DMSO.S159315","volume":"11","author":"R Singh","year":"2018","unstructured":"Singh, R. et al. Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases. Diab. Metab. Syndr. Obes. 11, 65\u201384 (2018).","journal-title":"Diab. Metab. Syndr. Obes."},{"key":"66296_CR63","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/hep.32119","volume":"75","author":"T Lin","year":"2022","unstructured":"Lin, T. et al. Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. Hepatology 75, 322\u2013337 (2022).","journal-title":"Hepatology"},{"key":"66296_CR64","unstructured":"Wu, C. et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat. Commun. 12, 6486 (2021)."},{"key":"66296_CR65","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","volume":"25","author":"ML Boland","year":"2019","unstructured":"Boland, M. L. et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J. Gastroenterol. 25, 4904\u20134920 (2019).","journal-title":"World J. Gastroenterol."},{"key":"66296_CR66","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","volume":"20","author":"HH Hansen","year":"2020","unstructured":"Hansen, H. H. et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 20, 210 (2020).","journal-title":"BMC Gastroenterol."},{"key":"66296_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50328-5","volume":"13","author":"HH Hansen","year":"2023","unstructured":"Hansen, H. H. et al. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Sci. Rep. 13, 23056 (2023).","journal-title":"Sci. Rep."},{"key":"66296_CR68","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","volume":"158","author":"BA Neuschwander-Tetri","year":"2020","unstructured":"Neuschwander-Tetri, B. A. Therapeutic landscape for NAFLD in 2020. Gastroenterology 158, 1984\u20131998 (2020).","journal-title":"Gastroenterology"},{"key":"66296_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","volume":"8","author":"MN Kristiansen","year":"2016","unstructured":"Kristiansen, M. N. et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J. Hepatol. 8, 673\u2013684 (2016).","journal-title":"World J. Hepatol."},{"key":"66296_CR70","doi-asserted-by":"crossref","unstructured":"Van Herck, M. A., Vonghia, L. & Francque, S. M. Animal models of nonalcoholic fatty liver disease-a starter\u2019s guide. Nutrients 9, 1072 (2017).","DOI":"10.3390\/nu9101072"},{"key":"66296_CR71","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/hep.22399","volume":"48","author":"JJ Maher","year":"2008","unstructured":"Maher, J. J., Leon, P. & Ryan, J. C. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology 48, 670\u2013678 (2008).","journal-title":"Hepatology"},{"key":"66296_CR72","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cell.2016.10.025","volume":"167","author":"P Li","year":"2016","unstructured":"Li, P. et al. Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell 167, 973\u2013984 e912 (2016).","journal-title":"Cell"},{"key":"66296_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2022.109217","volume":"112","author":"H Li","year":"2023","unstructured":"Li, H. et al. Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH. J. Nutritional Biochem. 112, 109217 (2023).","journal-title":"J. Nutritional Biochem."},{"key":"66296_CR74","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.26594","volume":"58","author":"T Ishimoto","year":"2013","unstructured":"Ishimoto, T. et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58, 1632\u20131643 (2013).","journal-title":"Hepatology"},{"key":"66296_CR75","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/hep.26299","volume":"57","author":"MB Vos","year":"2013","unstructured":"Vos, M. B. & Lavine, J. E. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57, 2525\u20132531 (2013).","journal-title":"Hepatology"},{"key":"66296_CR76","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cmet.2012.05.002","volume":"15","author":"JT Haas","year":"2012","unstructured":"Haas, J. T. et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 15, 873\u2013884 (2012).","journal-title":"Cell Metab."},{"key":"66296_CR77","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","volume":"61","author":"M Arrese","year":"2016","unstructured":"Arrese, M., Cabrera, D., Kalergis, A. M. & Feldstein, A. E. Innate immunity and Inflammation in NAFLD\/NASH. Dig. Dis. Sci. 61, 1294\u20131303 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"66296_CR78","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cmet.2021.09.004","volume":"33","author":"MA Febbraio","year":"2021","unstructured":"Febbraio, M. A. & Karin, M. Sweet death\u201d: Fructose as a metabolic toxin that targets the gut-liver axis. Cell Metab. 33, 2316\u20132328 (2021).","journal-title":"Cell Metab."},{"key":"66296_CR79","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/abbs\/gmt065","volume":"45","author":"R Xu","year":"2013","unstructured":"Xu, R., Tao, A., Zhang, S. & Zhang, M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys. Sin. (Shanghai) 45, 726\u2013733 (2013).","journal-title":"Acta Biochim Biophys. Sin. (Shanghai)"},{"key":"66296_CR80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov, K. et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 16, 145\u2013159 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"66296_CR81","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith, G. I. et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J. Clin. Investig. 130, 1453\u20131460 (2020).","journal-title":"J. Clin. Investig."},{"key":"66296_CR82","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fgene.2019.00472","volume":"10","author":"P Ortega-Prieto","year":"2019","unstructured":"Ortega-Prieto, P. & Postic, C. Carbohydrate sensing through the transcription factor ChREBP. Front. Genet. 10, 472 (2019).","journal-title":"Front. Genet."},{"key":"66296_CR83","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.cmet.2021.09.010","volume":"33","author":"MA Herman","year":"2021","unstructured":"Herman, M. A. & Birnbaum, M. J. Molecular aspects of fructose metabolism and metabolic disease. Cell Metab. 33, 2329\u20132354 (2021).","journal-title":"Cell Metab."},{"key":"66296_CR84","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1194\/jlr.M052308","volume":"55","author":"JA Duarte","year":"2014","unstructured":"Duarte, J. A. et al. A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice. J. Lipid Res. 55, 2541\u20132553 (2014).","journal-title":"J. Lipid Res"},{"key":"66296_CR85","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","volume":"579","author":"S Zhao","year":"2020","unstructured":"Zhao, S. et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 579, 586\u2013591 (2020).","journal-title":"Nature"},{"key":"66296_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15684-0","volume":"11","author":"KHM Roumans","year":"2020","unstructured":"Roumans, K. H. M. et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat. Commun. 11, 1891 (2020).","journal-title":"Nat. Commun."},{"key":"66296_CR87","doi-asserted-by":"crossref","unstructured":"Andres-Hernando, A. et al. Deletion of fructokinase in the liver or in the intestine reveals differential effects on sugar-induced metabolic dysfunction. Cell Metab. 32, 117\u2013127(2020).","DOI":"10.1016\/j.cmet.2020.05.012"},{"key":"66296_CR88","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516\u2013537 (2023).","journal-title":"J. Hepatol."},{"key":"66296_CR89","doi-asserted-by":"publisher","first-page":"nzab138","DOI":"10.1093\/cdn\/nzab138","volume":"5","author":"S Radhakrishnan","year":"2021","unstructured":"Radhakrishnan, S., Yeung, S. F., Ke, J. Y., Antunes, M. M. & Pellizzon, M. A. Considerations when choosing high-fat, high-fructose, and high-cholesterol diets to induce experimental nonalcoholic fatty liver disease in laboratory animal models. Curr. Dev. Nutr. 5, nzab138 (2021).","journal-title":"Curr. Dev. Nutr."},{"key":"66296_CR90","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1128\/MCB.00138-09","volume":"29","author":"S Guo","year":"2009","unstructured":"Guo, S. et al. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol. Cell Biol. 29, 5070\u20135083 (2009).","journal-title":"Mol. Cell Biol."},{"key":"66296_CR91","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1172\/JCI86013","volume":"126","author":"MC Petersen","year":"2016","unstructured":"Petersen, M. C. et al. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J. Clin. Investig. 126, 4361\u20134371 (2016).","journal-title":"J. Clin. Investig."},{"key":"66296_CR92","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1113\/JP271676","volume":"594","author":"SA Summers","year":"2016","unstructured":"Summers, S. A. & Goodpaster, B. H. CrossTalk proposal: Intramyocellular ceramide accumulation does modulate insulin resistance. J. Physiol. 594, 3167\u20133170 (2016).","journal-title":"J. Physiol."},{"key":"66296_CR93","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/nm.2049","volume":"15","author":"Z Cheng","year":"2009","unstructured":"Cheng, Z. et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat. Med. 15, 1307\u20131311 (2009).","journal-title":"Nat. Med."},{"key":"66296_CR94","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2017.12.016","volume":"27","author":"C Jang","year":"2018","unstructured":"Jang, C. et al. The Small intestine converts dietary fructose into glucose and organic acids. Cell Metab. 27, 351\u2013361 e353 (2018).","journal-title":"Cell Metab."},{"key":"66296_CR95","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep4.1356","volume":"3","author":"A Guillot","year":"2019","unstructured":"Guillot, A. & Tacke, F. Liver Macrophages: old dogmas and new insights. Hepatol. Commun. 3, 730\u2013743 (2019).","journal-title":"Hepatol. Commun."},{"key":"66296_CR96","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"66296_CR97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","volume":"29","author":"MA Febbraio","year":"2019","unstructured":"Febbraio, M. A. et al. Preclinical models for studying NASH-driven HCC: how useful are they?. Cell Metab. 29, 18\u201326 (2019).","journal-title":"Cell Metab."},{"key":"66296_CR98","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","volume":"2","author":"J Todoric","year":"2020","unstructured":"Todoric, J. et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat. Metab. 2, 1034\u20131045 (2020).","journal-title":"Nat. Metab."},{"key":"66296_CR99","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gutjnl-2014-306748","volume":"64","author":"J Verbeek","year":"2015","unstructured":"Verbeek, J. et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. Gut. 64, 673\u2013683 (2015).","journal-title":"Gut"},{"key":"66296_CR100","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.autrev.2018.06.008","volume":"17","author":"A Beringer","year":"2018","unstructured":"Beringer, A. & Miossec, P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun. Rev. 17, 1176\u20131185 (2018).","journal-title":"Autoimmun. Rev."},{"key":"66296_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.celrep.2021.108893","volume":"34","author":"O Stohr","year":"2021","unstructured":"Stohr, O., Tao, R., Miao, J., Copps, K. D. & White, M. F. FoxO1 suppresses Fgf21 during hepatic insulin resistance to impair peripheral glucose utilization and acute cold tolerance. Cell Rep. 34, 16 (2021).","journal-title":"Cell Rep."},{"key":"66296_CR102","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11901-016-0302-1","volume":"15","author":"J Wattacheril","year":"2016","unstructured":"Wattacheril, J. & Sanyal, A. J. Lean NAFLD: an underrecognized outlier. Curr. Hepatol. Rep. 15, 134\u2013139 (2016).","journal-title":"Curr. Hepatol. Rep."},{"key":"66296_CR103","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1111\/liv.15707","volume":"43","author":"RJ Klein","year":"2023","unstructured":"Klein, R. J., Viana Rodriguez, G. M., Rotman, Y. & Brown, R. J. Divergent pathways of liver fat accumulation, oxidation, and secretion in lipodystrophy versus obesity-associated NAFLD. Liver Int 43, 2692\u20132700 (2023).","journal-title":"Liver Int"},{"key":"66296_CR104","doi-asserted-by":"publisher","first-page":"14681","DOI":"10.1074\/jbc.M110.201061","volume":"286","author":"R Tao","year":"2011","unstructured":"Tao, R. et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 286, 14681\u201314690 (2011).","journal-title":"J. Biol. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66296-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66296-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66296-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:02:33Z","timestamp":1767049353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66296-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66296"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66296-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.F.W. is a scientific consultant for Housey Pharmaceutical Research Laboratories; M.A.L. is a member of Colorado Research Partners (CRP). Other authors declare no competing interests, including R.T., O.S., O.T., A.A.-H., W.Q., B.H., C.W., L.G., C.B., S.H., N.S., and K.D.C.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11595"}}